Lipella Pharmaceuticals Inc. LIPO
At closeNov 2, 2026, 4:00 PM EST
After hours · Nov 2, 4:00 PM ET
- YTD
- -99.67%
- 1 year
- -99.86%
- Market cap
- 2.77K
- Revenue (ttm)
- 507.20K
- EPS (ttm)
- -2.26
- Shares out
- 1.21M
- Forward P/E
- -0.97
- YTD return
- -99.67%
- 1-year return
- -99.86%
- Volume
- 160.09K
- Avg volume
- 910
- Open
- 0.058
- Previous close
- 0.0006
- Day's range
- 0.0327 – 0.058
- 52-week range
- 0.0002 – 0.545
- Price target
- 10.00 (+1666566.7%)
- Earnings date
- Feb 27, 2024
2Y -2.7194 (-99.98%)
Key statistics
- Enterprise value
- 1.34M
- PEG ratio
- 0.00
- Price / sales
- 7.39
- Price / book
- 0.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 27.90%
- Free cash flow
- -2.25M
- Total cash
- 1.19M
- Total debt
- 93.68K
- Return on equity
- -171.56%
- Short % of float
- 0.26%
- 50-day average
- 2.98
- 200-day average
- 4.27
Analyst view
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 27, 2024
Expected Feb 27, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.29 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.96 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -1.28 | — | — |
| Feb 27, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -1.84 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -2.16 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 9, 2024 | Maxim Group | init | — | Buy |
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lipella.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on LIPO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHANCELLOR MICHAEL B. | Officer, Director and Beneficial Owner | Stock Award(Grant) | Mar 12, 2024 | 877,637 |
| KAUFMAN JONATHAN | Chief Executive Officer | Purchase | May 13, 2024 | 898,849 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 0.36% | 4,315 | 13.38K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.26% | 3,114 | 9.65K | Sep 29, 2024 |
| HRT Financial LP | 0.18% | 2,202 | 6.83K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 962 | 2.98K | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 6 | 18 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.36% | 4,315 | 13.38K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.25% | 3,057 | 9.48K | Oct 30, 2024 |